KRAS and colorectal carcinoma: Moreover, the authors sequenced the HER-2 gene of 48 CRC patient-derived xenografts (PDX) samples that were cetuximab-resistant and wild-type (WT) for KRAS, NRAS, BRAF, and PIK3CA (quadruple WT): four of these PDXs had HER-2 mutations.